Chronic Malignancies Working Party - EBMT 2023
Challenges and Controversies in Allo-HCT for Myelofibrosis
Monday April 24th, 2023, 11:00 – 12:15
Location: Amphitheatre Bleu (On-site & Live stream)
Chairs: Donal McLornan & Kavita Raj
11:00 – 11:15 Utilising molecular data to guide the transplant decision in Myelofibrosis - Katja Sockel
11:15 – 11:30 Optimal management of splenomegaly pre-transplant - Nicola Polverelli
11:30 – 11:45 Selecting the best donor and stem cell source in allo-HCT for Myelofibrosis - Tomasz Czerw
11:45 – 12:00 Selecting the best conditioning regimen (+/- GVHD prophylaxis) in allo-HCT for Myelofibrosis - Juan Carlos Hernández Boluda
12:00 – 12:15 Panel Discussion and Questions

Chronic Malignancies Working Party - EBMT 2023
Business Meeting EBMT 2023
Monday April 24th, 2023, 7:00 – 08:45
Location: Room 241

---

Subcommittee Myelodysplastic Syndromes (MDS)

Chair: Marie Robin, Vice-chair: Christof Scheid, Vice-chair: Carmelo Gunnari, CMLM: Francesco Onida

Number of first allogeneic transplants for MDS registered at EBMT per year

Ongoing studies
Impact of comorbidities and body mass index on the outcomes of allogeneic hematopoietic stem cell transplantation in Myelofibrosis: an International analysis on behalf of the Chronic Malignancies Working Party of EBMT - Nicola Polverelli

A retrospective analysis of transplantation outcome for individuals with Advanced Systemic Mastocytosis (Adv-SM): Aggressive Systemic Mastocytosis (ASM), Systemic Mastocytosis with Associated Hematologic Disease (SM-AHD), Mast-Cell Leukemia (MCL) and Mast Cell Sarcoma (MCS) – Ghando Dama

Tresulfan in conditioning regimen before allogeneic HSCT in myelofibrosis patients – Marie Robin

Impact of CD34+ cell grafts content on clinical outcomes after family mismatched allo-HCT for myelofibrosis - Tomasz Czerw

Oral Session 17: MDS and MPNs – Wednesday April 26th, 2023, 12:30 – 13:45
Location: Room 153
16:15 – 16:24 OS17-01 Impact of Comorbidities and BMI on the outcomes of Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: An International Analysis on behalf of the CMWP of EBMT - Nicola Polverelli

Subcommittee Chronic Myeloid Leukemia (CML)

Chair: Yves Chalandon, Vice-chair: Guillermo Orti, Vice-chair: Hugues de Lavallade

Number of first allogeneic transplants for CML registered at EBMT per year

Studies starting soon
Impact of TKI discontinuation in CML patients who have previously restarted TKI following alloegenic HSCT - Hugues de Lavallade

Prognostic value of additional cytogenetic abnormalities at transplantation in CML patients - Jo Cao & Gaëlle Vertenoeil

Retrospective study on 2GTKi and 3GTKi after alloHSCT for CML in CP - Yves Chalandon

Upcoming manuscripts
Graft-versus-Host Disease Prophylaxis with Post Transplant Cyclophosphamide in Chronic Myeloid Leukemia patients undergoing Allogeneic Hematopoietic Cell Transplant from either an Unrelated or Mismatched Related Donor: a comparative study from the Chronic Malignancies Working Party of the EBMT (CMWP-EBMT) – Guillermo Orti

Haplo-identical Donor Allogeneic transplantation compared to other donor types for Ph+ Chronic Myeloid Leukemia: a Retrospective Analysis from the Chronic Malignancies Working Party (CMWP) of the EBMT – Francesco Onida

Recent publication

Data Quality Initiative (DQI)
Fifty-four centers, comprising 702 patients, have participated in the CML Data Quality Initiative. The data will be utilized for various studies in the future.

Oral Session 17: MDS and MPNs – Wednesday April 26th, 2023, 10:30 – 11:45
Location: Room 153
12:57 – 13:06 OS17-04 Outcomes of CMMI patients undergoing Allogeneic HCT in comparison with MDS patients - A Retrospective Analysis on behalf of the CMWP of the EBMT - Alicia Ravó

Oral Session 5: GvHD (Clinical) – Wednesday April 26th, 2023, 10:30 – 11:45
Location: Amphitheatre Bleu
11:15 – 11:24 OS05-06 GvHD Prophylaxis incorporating Methotrexate in Allo-HCT for Chronic Myeloid Malignancies and sAML: A Retrospective Analysis from the CMWP of the EBMT - Thomas Luft

Posters
P007 – Allogeneic Hematopoietic Cell Transplantation in Patients with Therapy-Related Myeloid Neoplasms following treatment for Lymphoma: A Study of the Chronic Malignancies Working Party of the EBMT - Mija Nabergoj

P046 – Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Therapy-Related Myeloid Neoplasms following treatment for Myeloma - Sarah Lawless

P303 Efficacy Of PTCY-Based GvHD Prophylaxis In Adults Older Than 55 With Myeloid Malignancies Undergoing allo-HCT According To Donor Type - Queralt Solas

Chronic Malignancies Working Party
CML & MDS & PH-neg MPN
Chair: Donal McLornan
Secretaries: Joanna Drozd-Sokolowska & Kavita Raj
Data management: Linda Koster, Laurien Baaij, Joe Tuffnell
Statisticians: Dirk-Jan Eikema, Luuk Gras, Simona Iacobelli

cmwpebmt@lumc.nl

www.ebmt.org